Maria Grazia Spillantini

Maria Grazia Spillantini's AcademicInfluence.com Rankings

Biology

#1688

World Rank

#2753

Historical Rank

Neuroscience

#389

World Rank

#407

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Maria Grazia Spillantini Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Maria Grazia Spillantini , is Professor of Molecular Neurology in the Department of Clinical Neurosciences at the University of Cambridge. She is most noted for identifying the protein alpha-synuclein as the major component of Lewy bodies, the characteristic protein deposit found in the brain in Parkinson's disease and dementia with Lewy bodies. She has also identified mutations in the MAPT gene as a heritable cause for frontotemporal dementia.

(See a Problem?)

Maria Grazia Spillantini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

α-Synuclein in Lewy bodies (1997) (4852)
Alpha-synuclein in Lewy bodies. (1997) (2847)
α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies (1998) (2581)
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease (1989) (2149)
A Century of Alzheimer's Disease (2006) (1770)
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. (1998) (1443)
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. (1998) (1031)
Identification of two distinct synucleins from human brain (1994) (1025)
Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms (1992) (1007)
Cloning and sequencing of the cDNA encoding an isoform of microtubule‐associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. (1989) (958)
Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans (1996) (918)
100 years of Lewy pathology (2013) (899)
Tau pathology and neurodegeneration (2013) (849)
Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies (1998) (802)
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia (2005) (764)
Tau protein pathology in neurodegenerative diseases (1998) (677)
Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein (2002) (615)
Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies (1998) (481)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. (1995) (438)
Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice (2010) (409)
Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. (1998) (409)
The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy (2000) (398)
Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. (1999) (395)
α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome (2001) (370)
Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* (2003) (357)
Synthetic filaments assembled from C‐terminally truncated α‐synuclein (1998) (354)
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein (2000) (346)
Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. (1997) (325)
Proteasomal degradation of tau protein (2002) (316)
The Synucleinopathies: Twenty Years On (2017) (307)
Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders (2006) (303)
Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. (1998) (278)
Filamentous nerve cell inclusions in neurodegenerative diseases (1998) (267)
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP. (1996) (267)
Tau Mutations Cause Frontotemporal Dementias (1998) (264)
Frontotemporal dementia and its subtypes: a genome-wide association study (2014) (262)
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. (2010) (251)
Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. (2010) (249)
PART is part of Alzheimer disease (2015) (243)
Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. (1999) (240)
Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. (1999) (224)
Phenotypic variation in hereditary frontotemporal dementia with tau mutations (1999) (222)
Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system. (1992) (222)
The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. (2000) (218)
Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures (1999) (209)
Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. (2004) (191)
Tau pathology in a family with dementia and a P301L mutation in tau. (1999) (187)
Depletion of Perineuronal Nets Enhances Recognition Memory and Long-Term Depression in the Perirhinal Cortex (2013) (186)
Tau gene mutation in familial progressive subcortical gliosis (1999) (184)
Tau Proteins and Neurofibrillary Degeneration (1991) (181)
Induction of the unfolded protein response by α‐synuclein in experimental models of Parkinson’s disease (2011) (180)
Interaction of tau protein with the dynactin complex (2007) (178)
Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations (2007) (175)
Tau gene mutations: dissecting the pathogenesis of FTDP-17. (2002) (170)
Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. (2001) (168)
Pick’s disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment (1996) (167)
Tau Gene Mutation K257T Causes a Tauopathy Similar to Pick's Disease (2000) (166)
Stress-activated protein kinase-3 interacts with the PDZ domain of alpha1-syntrophin. A mechanism for specific substrate recognition. (1999) (164)
Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies (2013) (161)
Comparison of the neurofibrillary pathology in Alzheimer’s disease and familial presenile dementia with tangles (1996) (161)
Impaired intracellular trafficking defines early Parkinson's disease (2015) (160)
Synthetic filaments assembled from C-terminally truncated alpha-synuclein. (1998) (158)
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease (2007) (155)
Increased Dickkopf‐1 expression in transgenic mouse models of neurodegenerative disease (2010) (147)
A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies (2000) (144)
Propagation of Tau aggregates (2017) (140)
Atypical, non-standard functions of the microtubule associated Tau protein (2017) (138)
Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. (2000) (138)
Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression. (1989) (137)
Clinical, imaging and pathological correlates of a hereditary deficit in verb and action processing. (2006) (136)
Pick's disease associated with the novel Tau gene mutation K369I (2001) (135)
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. (2007) (135)
Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) (2000) (132)
Alpha‐synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease – a systematic review (2014) (131)
Frontotemporal dementia: implications for understanding Alzheimer disease. (2012) (130)
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. (2012) (126)
Pathogenesis of the Tauopathies (2011) (119)
Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. (2008) (116)
A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD‐Kumamoto) (2000) (116)
Synaptic failure and α‐synuclein (2016) (114)
Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35. (1995) (113)
Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. (2008) (113)
Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability (2011) (111)
Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations (2015) (108)
Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration (2009) (107)
The role of tau in the pathological process and clinical expression of Huntington’s disease (2015) (106)
Chromosome 3 linked frontotemporal dementia (FTD-3) (2002) (106)
Segmental and developmental regulation of a presumptive T-cell oncogene in the central nervous system (1990) (105)
PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans. (1996) (105)
Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies (2017) (105)
Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology (2015) (104)
Argyrophilic grain disease: widespread hyperphosphorylation of tau protein in limbic neurons (1997) (102)
Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia (2018) (97)
Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy (2010) (97)
Alpha‐synuclein dysfunction in Lewy body diseases (2005) (94)
Lewy body diseases and multiple system atrophy as α-synucleinopathies (1998) (91)
Physiological and pathological properties of α-synuclein (2007) (91)
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons (2015) (90)
In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain1 (2008) (89)
Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice (2009) (86)
Localization of the Alz-50 epitope in recombinant human microtubule-associated protein tau (1991) (86)
Molecular dissection of the paired helical filament (1995) (85)
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy (2009) (84)
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family (2007) (84)
A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia (2006) (83)
Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17. (1997) (81)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. (2018) (81)
Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics. (2000) (78)
Early behavioural markers of disease in P301S tau transgenic mice (2010) (75)
Tau Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP‐17): Their Relevance for Understanding the Neurogenerative Process (2000) (75)
Anti-amyloid Compounds Inhibit α-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA)* (2014) (74)
Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant (2013) (72)
Frontotemporal Dementia with Tau Pathology (2007) (72)
Microtubule-associated protein tau, heparan sulphate and α-synuclein in several neurodegenerative diseases with dementia (1999) (71)
Cathepsin D displays in vitro β-secretase-like specificity (1997) (70)
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation (2011) (70)
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit (2016) (68)
Neurodegeneration and the ordered assembly of α-synuclein (2017) (67)
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model (2019) (67)
Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy (2016) (66)
Characterization of endopeptidase 3.4.24.11 ("enkephalinase") activity in human plasma and cerebrospinal fluid. (1990) (63)
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice (2012) (63)
Labeling and identifying cell-specific proteomes in the mouse brain (2017) (62)
From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. (2001) (62)
The synovium of transgenic arthritic mice expressing human tumor necrosis factor contains a high level of nerve growth factor. (1993) (61)
Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau (2012) (60)
Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. (1990) (60)
Tau mutations in familial frontotemporal dementia. (2000) (59)
Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. (1990) (59)
Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions (2017) (58)
Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are α-synucleinopathies (1999) (58)
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome (2012) (58)
Electrophysiology and Pharmacology of Striatal Neuronal Dysfunction Induced by Mitochondrial Complex I Inhibition (2008) (56)
Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra (2013) (56)
Tau gene mutations and neurodegeneration. (2001) (56)
Developmentally regulated and tissue specific expression of mRNAs encoding the two alternative forms of the LIM domain oncogene rhombotin: evidence for thymus expression. (1991) (55)
Physiological and pathological properties of alpha-synuclein. (2007) (55)
Substance P-like immunoreactivity in capsaicin-sensitive structures of the rat thymus (1987) (55)
Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684. (1999) (54)
Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. (1998) (53)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo (2019) (51)
Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy (2016) (50)
Distribution of β‐nerve growth factor receptors in the human basal forebrain (1989) (48)
[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation (2016) (47)
Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology (2019) (47)
Cathepsin D displays in vitro beta-secretase-like specificity. (1997) (45)
Expression and cellular localization of amyloid β-protein precursor transcripts in normal human brain and in Alzheimer's disease (1989) (44)
Molecular dissection of the neurofibrillary lesions of Alzheimer's disease. (1995) (44)
Intermittent Hypoendorphinaemia in Migraine Attack (1982) (44)
Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration (2017) (43)
The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice (2017) (43)
Substance P Mechanism in Cluster Headache: Evaluation in Plasma and Cerebrospinal Fluid (1985) (42)
Late onset distal axonal swelling in YFP-H transgenic mice (2009) (42)
In vivo 'enkephalinase' inhibition by acetorphan in human plasma and CSF. (1986) (41)
Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. (1999) (41)
A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 +3‐splice site mutation in the tau gene: clinical and pathological features (2000) (41)
Tau protein in familial and sporadic diseases (2007) (40)
Worldwide distribution of PSEN1 Met146Leu mutation (2010) (39)
Tau protein in Alzheimer's disease. (1995) (39)
Association between tau H2 haplotype and age at onset in frontotemporal dementia. (2005) (38)
Tau and α-Synuclein Inclusions in a Case of Familial Frontotemporal Dementia and Progressive Aphasia (2005) (38)
Impairments in impulse control in mice transgenic for the human FTDP-17 tauV337M mutation are exacerbated by age. (2007) (38)
A novel leukoencephalopathy associated with tau deposits primarily in white matter glia (2003) (37)
Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis (2009) (36)
The Effect of Truncated Human α-Synuclein (1–120) on Dopaminergic Cells in a Transgenic Mouse Model of Parkinson's Disease (2007) (36)
Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells (2018) (35)
Ordered Assembly of Tau Protein and Neurodegeneration. (2019) (35)
Synucleinopathies: past, present and future (2016) (34)
Intraneuronal filamentous tau protein and α-synuclein deposits in neurodegenerative diseases (1998) (34)
Closing the tau loop: the missing tau mutation. (2015) (34)
Tau and Parkinson disease. (2001) (33)
The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons (2013) (33)
Tau Protein in Frontotemporal Dementia Linked to Chromosome 3 (FTD‐3) (2003) (33)
Progress in Hereditary Tauopathies: A Mutation in the Tau Gene (G389R) Causes a Pick Disease‐like Syndrome (2000) (33)
Localization of Endo‐Oligopeptidase (EC 3.4.22.19) in the Rat Nervous Tissue (1990) (33)
Abnormal tau phosphorylation in primary progressive multiple sclerosis (2010) (33)
The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. (2007) (33)
Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates (2021) (32)
Tau Pathology is Present In Vivo and Develops In Vitro in Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies (2013) (32)
Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction (2010) (32)
The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice (2015) (31)
Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid. (1987) (31)
Biochemical, anatomical and functional correlates of postnatal development of the capsaicin-sensitive innervation of the rat urinary bladder. (1988) (30)
Early‐onset Dementia with Lewy Bodies (2004) (30)
Parkinson's disease as a member of Prion-like disorders. (2015) (30)
Similar early clinical presentations in familial and non-familial frontotemporal dementia (2004) (30)
A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers (2018) (30)
The Transcellular Propagation and Intracellular Trafficking of α-Synuclein. (2017) (29)
Clinical comparison of progressive aphasia associated with Alzheimer versus FTD-spectrum pathology (2010) (29)
The correlation between sensory-efferent functions mediated by the capsaicin-sensitive neurons and substance P content of the rat urinary bladder (1987) (29)
Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (29)
Behavioural deficits in transgenic mice expressing human truncated (1–120 amino acid) alpha-synuclein (2015) (28)
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? (2004) (28)
Frontotemporal lobar degeneration through loss of progranulin function. (2006) (25)
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure (2015) (24)
Enkephalinase and angiotensin converting enzyme activities in human venous and arterial plasma (1986) (23)
Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity (2020) (22)
Nurr1 co‐localizes with EphB1 receptors in the developing ventral midbrain, and its expression is enhanced by the EphB1 ligand, ephrinB2 (2005) (21)
Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration (2019) (21)
Stress-activated Protein Kinase-3 Interacts with the PDZ Domain of α1-Syntrophin (1999) (21)
Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy as α-Synucleinopathies. (2001) (20)
Synaptic dysfunction in synucleinopathies. (2013) (20)
Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. (1998) (19)
Heritability in frontotemporal tauopathies (2019) (19)
Mutations in the tau gene (MAPT) in FTDP-17: the family with Multiple System Tauopathy with Presenile Dementia (MSTD). (2006) (19)
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation (2015) (17)
Super-resolution imaging reveals α-synuclein seeded aggregation in SH-SY5Y cells (2021) (17)
The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration (2021) (17)
Tau protein and Alzheimer's disease (1994) (17)
Thiorphan increases capsaicin-evoked release of substance P from slices of dorsal spinal cord of guinea pig (1989) (16)
a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (ubiquitinysarkosyl-insoluble filamentsyimmunoelectron microscopy) (1998) (16)
Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia (2011) (16)
The human glutamate receptor cDNA GluR1: cloning, sequencing, expression and localization to chromosome 5. (1992) (15)
Frontotemporal Dementia Linked to Chromosome 3 (2004) (13)
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial (2022) (13)
L444P Gba1 mutation increases formation and spread of α-synuclein deposits in mice injected with mouse α-synuclein pre-formed fibrils (2020) (13)
Synthesis of polymeric nanocapsules by radical UV-activated interface-emulsion polymerization (2016) (12)
Tau gene mutations and tau pathology in frontotemporal dementia and parkinsonism linked to chromosome 17. (2001) (12)
Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system (2016) (12)
pFTAA: a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons (2015) (12)
A Brief History of Tau. (2015) (11)
Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice (2011) (11)
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate (2020) (11)
Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology. (2011) (10)
Phenotypic Variation of Autosomal-Dominant Corticobasal Degeneration (2012) (10)
TAU GENE MUTATIONS IN FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17 (2003) (9)
Measurement of catecholamines, met-enkephalin, somatostatin and substance P-like immunoreactivities in 12 human pheochromocytomas (1988) (9)
The Role of Rab Proteins in Parkinson’s Disease Synaptopathy (2022) (9)
Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model (2013) (9)
Tauopathies and α-Synucleinopathies (2000) (8)
CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice (2020) (8)
Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes (2021) (8)
Synucleinopathies and Tauopathies (2012) (8)
Increase in substance P levels in the lung of old rats. (1988) (8)
Non‐Alzheimer Degenerative Dementias (1998) (7)
Mutations in the Tau gene cause frontotemporal dementia (1999) (7)
Validation of the new pathology staging system for progressive supranuclear palsy (2021) (7)
Slowly progressive behavioural presentation in two UK cases with the R406W MAPT mutation (2016) (7)
Molecular neuropathology of Alzheimer's disease:In situ hybridization studies (1990) (6)
Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models (2021) (6)
Post-translational modifications of microtubule-and growth-associated proteins in nerve regeneration and neuropathy (2009) (5)
Hypernociceptive syndromes and pharmacological inhibition of endogenous opioid degradation. (1986) (5)
Tau Protein and Frontotemporal Dementias. (2021) (5)
Distribution of beta-nerve growth factor receptors in the human basal forebrain. (1989) (5)
Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease (1995) (5)
Met-enkephalin-like immunoreactivity (MELI) and enkephalinase activity (EKA) in cord blood and newborns in the first hours of life. (1986) (4)
The Alzheimer tangle — 100 years on. (2006) (4)
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype (2022) (4)
Inhibition of penicillin-induced EEG discharge by low doses of morphine or naloxone in the rabbit. Evidence for a possible non-opioid receptor-mediated mechanism at the sensorimotor cortex (1986) (4)
Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis (2020) (3)
[Familial fronto-temporal dementia with brain stem ubiquitin-positive neuronal inclusions]. (2004) (3)
In Vivo 18F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy (2021) (3)
In Vivo 18 F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy (2022) (3)
Expression and cellular localization of amyloid beta-protein precursor transcripts in normal human brain and in Alzheimer's disease. (1989) (3)
‘Enkephalinase’ in Migraine and Opiate Addiction (1985) (2)
Depopulation of α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model (2018) (2)
Unpicking frontotemporal lobar degeneration. (2011) (2)
Influence of Drug-Carrier Polymers on Alpha-Synucleinopathies: A Neglected Aspect in New Therapies Development (2018) (2)
Organisation and Tyrosine Hydroxylase and Calretinin Immunoreactivity in the Main Olfactory Bulb of Paca (Cuniculus paca): A Large Caviomorph Rodent (2015) (2)
Tracking tau fibrillogenesis and consequent primary phagocytosis of neurons mediated by microglia in a living tauopathy model (2020) (2)
Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (2)
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease (2011) (2)
HEREDITARY MULTIPLE SYSTEM DEGENERATION WITH PRESENILE DEMENTIA: TAU (τ) ABNORMALITIES IN NERVE CELLS AND OLIGODENDROGLIA (1996) (2)
Introduction to α‐Synucleinopathies (2011) (1)
Novel Cathepsin D Inhibitors Prevent the β-Secretase-Derived Intracellular Formation of a 12 kDa Potentially Amyloidogenic Product in Human Cells (1997) (1)
Neurodegenerative α-Synucleinopathies (2005) (1)
Atypical, non-standard functions of the microtubule associated Tau protein (2017) (1)
322 Inhibitors of cathepsin D block β-secretase-like cleavage in human cells (1996) (1)
Synthetic ¢laments assembled from C-terminally truncated K-synuclein (1998) (1)
Mapping the binding site topology of amyloid protein aggregates using multivalent ligands† (2021) (1)
A tribute to John Q. Trojanowski (1946–2022), neuropathologist extraordinaire (2022) (1)
Preparation and characterization and radiolabelling of multivalent ligands towards positron emission tomography imaging of oligomeric forms of misfolded proteins involved in neurodegenerative diseases (2022) (1)
Immune-related genetic enrichment in frontotemporal dementia (2017) (1)
Perineuronal net digestionwith chondroitinase restores memory inmice with tau pathology (2014) (1)
PET does not accurately support the staging of progressive supranuclear palsy (2021) (1)
Editorial: Tau Pathology in Neurological Disorders (2021) (1)
Salivary α‐Synuclein RT‐QuIC Correlates with Disease Severity in de novo Parkinson's Disease (2022) (1)
Subject Index Vol. 17, 2004 (2004) (1)
Tau aggregation and its relation to selected forms of neuronal cell death (2021) (1)
Molecular neuropathology in familial and sporadic frontotemporal dementia (2007) (1)
NMR STRUCTURE OF TAU EXON 10 SPLICING REGULATORY ELEMENT RNA (1999) (1)
Early maturation and distinct tau pathology in IPSC-derived neurons from patients with MAPT mutations (2015) (1)
P1-086 Hyperphosphorylated tau accumulates in retinal ganglion neurons of P301S tau transgenic mice (2006) (1)
78 Tauopathies: a single therapy for all? (2012) (1)
Evaluation Of Csf Neuropeptides And Peptidase Activities In Primary Headaches (1987) (1)
Substance P- and Somatostatin-Like Immunoreactivity in Maternal and in Umbilical Cord Plasma and in Amniotic Fluid (1987) (0)
Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions (2017) (0)
Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (0)
Super-resolution imaging reveals α-synuclein seeded aggregation in SH-SY5Y cells (2021) (0)
NEURONS WITH TAU AGGREGATES EXPOSE PHOSPHATIDYLSERINE AND ARE PHAGOCYTOSED LIVE BY MICROGLIA (2018) (0)
Cyclic Amplification ( PMCA )-Synuclein Aggregation Induced by Protein α Anti-amyloid Compounds Inhibit Neurobiology : (2014) (0)
Correction: Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease (2012) (0)
Propagation of Tau aggregates (2017) (0)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia (2018) (0)
20S Proteasomal degradation of α-synuclein does not generate the non-β-amyloid plaque component (NAC) (2002) (0)
Organisation and Tyrosine Hydroxylase and Calretinin Immunoreactivity in the Main Olfactory Bulb of Paca (Cuniculus paca): A Large Caviomorph Rodent (2015) (0)
Enkephalinase Activity in Plasma and Cerebrospinal Fluid in Primary Headache (1985) (0)
Changes to Tau Phosphorylation in Experimental Rat Glaucoma (2009) (0)
P1-084 Use of YFP imaging to study axon pathology in animal models of Alzheimer’s disease (2006) (0)
Thermosensitive Hydrogels for the Intranasal Administration of Drugs to the Central Nervous System (2015) (0)
Nanoscopic characterization of individual endogenous protein aggregates in human neuronal cells (2018) (0)
New SNCA mutation and structures of α-synuclein filaments from juvenile-onset synucleinopathy (2022) (0)
Neurodegenerative Diseases: What Is to Be Done? (2015) (0)
[Plasma beta endorphin in man during partial immersion in water using the therapeutic method]. (1986) (0)
Substance P Empty Neuron: A Conceptualization of Organic and Functional Deafferentation Syndromes (1987) (0)
S2-03-01: Tau-associated neurodegeneration in Alzheimer's Disease and tauopathy (2008) (0)
Tau pathology in families with frontotemporal dementia and Parkinsonism linked to chromosome 17 (2000) (0)
Screening of agents for the treatment of Alzheimer's disease (1997) (0)
Plasma beta-endorphin in normal and premature newborns. (1984) (0)
Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity (2020) (0)
Topographical relationship between f 8-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease ( molecular pathology / amyloid fibrils / paired helical filaments ) (0)
Parkinson's disease-mild cognitive impairment (PD-MCI) and Parkinson's disease Dementia (PDD) (2012) (0)
Enkephalinase and Angiotensin Converting Enzyme Inhibition in Migraine (1989) (0)
ANATOMY OPTION A: R ESEARCH IN DEVELOPMENTAL BIOLOGY AND NEUROSCIENCE (2006) (0)
The missing tau mutation: +15 exon 10/intron 10 boundary of MAPT stem loop structure in an Irish family with FTDP-17 (2013) (0)
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease (2016) (0)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
Molecular Biology of Lewy Body Formation (2002) (0)
Title Progression of Parkinson ’ s disease pathology is reproduced by intragastric administration of rotenone in mice Authors and Affiliations (2010) (0)
A Clinical, Pathological And Molecular Study Of A Frontotemporal Dementia Sporadic Case (2008) (0)
Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic Neurons (2022) (0)
Edinburgh Explorer Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction (2018) (0)
Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (0)
Contents Vol. 8, 2011 (2011) (0)
Tauopathy-induced retinal dysfunction in the P301S mutant human tau transgenic mouse (2013) (0)
PICK DISEASE WITH GLIAL TAU INCLUSIONS IN THE WHITE MATTER (1999) (0)
Nervegrowthfactor mRNA andprotein increase inhypothalamus inamousemodelofaggression (1989) (0)
Natural and synthetic hydrogels in the treatment of neurodegenerative diseases (2015) (0)
Disorders of Brain and Mind: The neurobiology of the tauopathies (2003) (0)
Chapter 4 Tau Protein and the Dementias (2007) (0)
Cover Feature: Nanoscopic Characterisation of Individual Endogenous Protein Aggregates in Human Neuronal Cells (ChemBioChem 19/2018) (2018) (0)
Neutral-metalloendopeptidase ('enkephalinase') in maternal plasma and in amniotic fluid during pregnancy and labour (1987) (0)
Nanofibrous substrates for the development of 3D-complex structure mimicking the multicellular composition of brain (2017) (0)
Novel, Long Sought Splice Site Mutation at Exon 10/Intron 10 Boundary of MAPT Stem Loop Structure in a Family with FTDP-17 (P05.056) (2013) (0)
Alterations of neurotrophin signaling in the retina of the P301S mutant human tau transgenic mouse (2013) (0)
Clinical pharmacology of inhibitors of enkephalin degrading enzymes: A potential analgesic drug (1992) (0)
Neurotrophin signaling is altered in the retina of the P301S mutant human tau transgenic mouse (2013) (0)
Tauopathy-induced retinal dysfunction in the P301S mutant human tau transgenic mouse (2013) (0)
PHOSPHATIDYLSERINE EXPOSURE ON CULTURED DORSAL ROOT GANGLIA NEURONS FROM P301S TAU MICE SUGGEST PHAGOPTOSIS AS AN EXTRINSIC ROUTE OF CELL DEATH IN TAUOPATHY (2016) (0)
Human stem cell-derived neurones as a model to study tau function and dysfunction (2011) (0)
MOLECULAR BIOLOGY OF LEWY BODY FORMATION a-Synudeinopathies (2002) (0)
Editorial Board and Contents (2015) (0)
Contents Vol. 17, 2004 (2004) (0)
Neurodegeneration and the ordered assembly of α-synuclein (2017) (0)
AND ARE PHAGOCYTOSED LIVE BY MICROGLIA (0)
Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression ( trophic interactions / gene transcription / in situ hybridization ) (0)
HPLC and Immunohistochemical Characterization of Substance P-Like Immunoreactivity in a Human Pheochromocytoma (1987) (0)
Isoforms of the microtubule-associa ted protein tau: distribution in control and Alzheimer's disease brains (1990) (0)
β-Endorphin during spontaneous and oxytocin-induced labour (1986) (0)
638 Characterization of tau-positive fibrillary pathology in familial multiple system degeneration with presenile dementia (1996) (0)
Targeting tau degradation: a viable therapeutic approach? (2023) (0)
P4-119 Characterization of ubiquitin positive inclusions in frontotemporal dementia (2006) (0)
A tribute to John Q. Trojanowski (1946-2022), neuropathologist extraordinaire. (2022) (0)
Further Biochemical Investigations in Migraine and Opiate Addiction (1985) (0)
Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system (2011) (0)
Screening of active ingredients for treatment of alzheimer's disease (1997) (0)
Tau Hyperphosphorylation In Retinal Ganglion Cells Is Associated With Reduced Axonal Transport And Enhanced Sensitivity To Excitotoxic Injury (2011) (0)
Synapsin III alterations in Parkinson's disease (2016) (0)
P3-193 Genotype-phenotype relationship is lacking in families with PS1-Met146Leu founder mutation (2006) (0)
Mapping the binding site topology of amyloid protein aggregates using multivalent ligands. (2021) (0)
Need to Pinpoint Major Speci fi c Pathologies and Circuit Dysfunction in Neurodegenerative Diseases over the Life Span and to Identify Dysfunctional Circuits (2015) (0)
GENE MAP OF THE MSTD (MULTIPLE SYSTEM TAUOPATHY WITH PRESENILE DEMENTIA) REGION ON HUMAN CHROMOSOME 17q21–22 (1997) (0)
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease (2017) (0)
Cell-mediated Neuroprotection in P301S Human Tau Transgenic Mice, a Model of Human Tauopathy (2010) (0)
Procedes et compositions pour le diagnostic des pathologies tau (1999) (0)

This paper list is powered by the following services:

Other Resources About Maria Grazia Spillantini

en.wikipedia.org

What Schools Are Affiliated With Maria Grazia Spillantini?

Maria Grazia Spillantini is affiliated with the following schools: